Control of nausea and vomiting after chemotherapy: What is the evidence?

Internal Medicine Journal

Volumn 32, Issue 8, 2002, Pages 401-407

  Bartlett, N ^a   Koczwara, Bogda ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Chemotherapy; Nausea; Vomiting

Indexed keywords

1 ASPARAGINASE; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; STREPTOZOCIN; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG;

CHEMOTHERAPY; DRUG RESEARCH; HUMAN; NAUSEA; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; NAUSEA; NEOPLASMS; PATIENT SATISFACTION; PRIMARY PREVENTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VOMITING;

EID: 0036965492     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2002.00259.x     Document Type: Review

References (44)

1. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971-94.
2. Delfavero A, Roila F, Deangelis V et al. Transferability to clinical practice of the results of controlled clinical trials - the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 1998; 9: 759-65.
3. Gralla RJ, Navari RM, Hesketh PJ et al. Single dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16: 1568-73.
4. Perez EA, Hesketh P, Sandbach J et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998; 16: 754-60.
5. Quality of Care and Health Outcomes Committee, NHMRC. Guidelines for the development and implementation of clinical practice guidelines. Canberra: AGPS; 1995.
6. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacological management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 1999; 56: 729-64.
7. Dicato MA. Medical Management of Cancer Treatment Induced Emesis. London: Martin Dunitz Ltd; 1998.
8. Roila F, Delfavero A, Gralla RJ et al. Prevention of chemotherapy and radiotherapy-induced emesis - results of the Perugia consensus conference. Ann Oncol 1998; 9: 811-19.
9. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 1997; 15: 116-23.
10. Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Cancer 1989; 64: 1117-22.
11. Roila F, Boschetti E, Tonato M et al. Predictive factors of delayed emesis in cisplatin-treated patients: antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991; 14: 238-42.
12. Dubois A, Vach W, Kiechle M, Cramergiraud U, Meerpohl HG. Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology (Huntington) 1996; 53: 46-50.
13. Hursti TJ, Avall-Lundqvist E, Borjeson S, Fredrikson M, Furst CJ, Peterson C. Impact of tumour burden on chemotherapy-induced nausea and vomiting. Br J Cancer 1996; 74: 1114-19.
14. Heron JF, Goedhals L, Jordaan JP, Cunningham J, Cedar E. Oral granisetron alone and in combination with dexamethasone: a double-blind randomised comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann Oncol 1994; 5: 579-84.
15. Lofters WS, Pater JL, Zee B et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997; 15: 2966-73.
16. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs 1998; 55: 173-89.
17. Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050-7.
18. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
19. Cassileth PA, Lusk EJ, Torri S, DiNubile N, Gerson AL. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med 1983; 143: 1347-9.
20. The Italian Group for Antiemetic Research. Double-blind dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998; 16: 2937-42.
21. Mabro M, Granisetron PK. Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group Granisetron. Bull Cancer 1999; 86: 295-301.
22. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatin-based chemotherapy - effects of antiemetics. J Clin Pharm 1993; 33: 691-7.
23. Clark RA, Gralla RJ. Delayed emesis - a dilemma in antiemetic control. Support Care Cancer 1993; 1: 182-5.
24. Sorbe BG, Berglind A, Andersson H et al. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Cancer 1998; 83: 1022-32.
25. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and induced by chemotherapy. N Engl J Med 2000; 342: 1554-9.
26. The Italian Multicenter Study Group. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. Anticancer Drugs 1999; 10: 465-70.
27. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 1998; 9: 661-6.
28. Latreille J, Pater J, Johnston D et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 1174-8.
29. The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997; 15: 124-30.
30. Buser KS, Joss RA, Piquet D et al. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. Ann Oncol 1993; 4: 475-9.
31. Levitt M, Warr D, Yelle L et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 1993; 328: 1081-4.
32. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999; 340: 190-5.
33. Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 1995; 18: 170-5.
34. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328: 1076-80.
35. Pizzo BA, Pisters KMW, Miller VA et al. Oral cisapride for the control of delayed vomiting following high-dose cisplatin. Support Care Cancer 1999; 7: 44-6.
36. Hesketh PJ, Gralla RJ, Webb RT et al. Randomised phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999; 17: 338-43.
37. Mantovani G, Curreli L, Macci'o A et al. Prevention of nausea and vomiting (N & V) in cancer patients receiving cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N & V - a first clinical report. Anticancer Res 1999; 19: 3495-502.
38. Rizk AN, Hesketh PJ. Antiemetics for cancer chemotherapy-induced nausea and vomiting: agents in development. Drugs R D 1999; 2: 229-35.
39. Ladabaum U, Hasler WL. Novel approaches to the treatment of nausea and vomiting. Dig Dis 1999; 17: 125-32.
40. Vickers A. Evidence based medicine and complementary medicine. ACP Journal Club 1999; 130: A13-14.
41. Vickers A. Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. J Royal Soc Med 1996; 6: 303-11.
42. Mayer DJ. Acupuncture: An evidence-based review of the clinical literature. Annual Review Med 2000; 51: 49-63.
43. Dundee JW, Yang J. Prolongation of the antiemetic action of P6 acupuncture by acupressure in patients having cancer chemotherapy. J Royal Soc Med 1990; 83: 360-2.
44. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaes 2000; 84: 367-71.